Related Experiment Videos
A new assay to assess steroid-hormone responsiveness in head and neck cancer
Abstract:
A new assay has been developed to predict the effectiveness of steroid-hormone therapy in various tumors. The Biopsy Nuclear Binding assay measures the amount of biologically active receptor that binds both steroid hormone and acceptor sites in the nucleus. This assay does not measure the entire receptor population, only those that are biologically active; therefore, it should more accurately predict the response to steroid-hormone therapy. We applied this assay effectively in breast and endometrial carcinoma. Preliminary studies have shown that 40% of patients with head and neck squamous-cell carcinomas have biologically active (nuclear bound) progesterone receptors. If nuclear binding predicts a remission with hormonal therapy, then the quality of life of appropriately selected patients could greatly improve.
Insights
A novel Biopsy Nuclear Binding assay predicts steroid-hormone therapy effectiveness by measuring biologically active nuclear receptors. This method shows promise for improving patient selection and outcomes in various cancers.
Area of Science:
- Oncology
- Endocrinology
- Biochemistry
Background:
- Steroid-hormone therapies are crucial for treating various cancers.
- Accurate prediction of patient response to these therapies remains a challenge.
- Current assays may not fully capture the biologically active receptor levels crucial for treatment efficacy.
Purpose of the Study:
- To develop and validate a new assay for predicting steroid-hormone therapy effectiveness.
- To measure biologically active nuclear receptors involved in steroid hormone binding.
- To improve patient selection for hormonal therapy and enhance treatment outcomes.
Main Methods:
- Development of the Biopsy Nuclear Binding assay.
- Quantification of biologically active receptors binding to steroid hormones and nuclear acceptor sites.
- Application of the assay in breast, endometrial, and head and neck carcinomas.
Main Results:
- The Biopsy Nuclear Binding assay effectively measures biologically active nuclear receptors.
- The assay was successfully applied to breast and endometrial carcinoma samples.
- Preliminary data indicate 40% of head and neck squamous-cell carcinoma patients possess biologically active progesterone receptors.
Conclusions:
- The Biopsy Nuclear Binding assay offers a more accurate prediction of steroid-hormone therapy response.
- This assay has potential applications in various tumor types, including breast, endometrial, and head and neck cancers.
- Accurate patient selection using this assay could significantly improve quality of life through effective hormonal therapy.